Journal article
Combined Treatment with a WNT Inhibitor and the NSAID Sulindac Reduces Colon Adenoma Burden in Mice with Truncated APC
MC Faux, J Weinstock, S Gogos, E Prato, AI Azimpour, R O’Keefe, Y Cathcart-King, AL Garnham, M Ernst, A Preaudet, M Christie, TL Putoczki, M Buchert, AW Burgess
Cancer Research Communications | Published : 2022
Abstract
Adenomatous polyposis coli (APC) truncations occur in many colorectal cancers and are often associated with immune infiltration. The aim of this study was to determine whether a combination of Wnt inhibition with anti-inflammatory (sulindac) and/or proapototic (ABT263) drugs can reduce colon adenomas. Apcmin/+ and doublecortin-like kinase 1 (Dclk1)Cre/+;Apcfl/fl mice were exposed to dextran sulphate sodium (DSS) in their drinking water to promote the formation of colon adenomas. Mice were then treated with either a Wnt-signaling antagonist pyrvinium pamoate (PP), an anti-inflammatory agent sulindac or proapoptotic compound ABT263 or a combination of PP+ABT263, or PP+sulindac. Colon adenoma f..
View full abstractGrants
Awarded by Walter and Eliza Hall Institute
Funding Acknowledgements
This research was funded by NHMRC, program grant no. 487922 (to A.W. Burgess) and the work was supported generously by WEHI and the Ludwig Institute for Cancer Research. The funding body had no role in the design of the study, collection, analysis or interpretation of data or in writing the article. We would like to acknowledge the work of our colleagues in the animal breeding and experimentation center at WEHI, without their care and attention to detail these experiments would not have been possible.